Recent years have seen unprecedented growth in the understanding of genetic and genomic changes in melanoma. Much of the information is from next-generation sequencing (NGS), particularly exome sequencing, and has been instrumental in the discovery of new cancerdriver genes. These NGS studies have corroborated the previously identified frequent recurrent somatic mutations in BRAF and NRAS and revealed new melanoma mutations, including a recurrent mutation in RAC1 (RAC1 P29S ), the third most frequent activating mutation in sun-exposed melanoma after BRAF and NRAS, and the most frequent recurring mutation in the Rho GTPase family 1-3 . The mutant protein RAC1 P29S is a fast-cycling GTPase favoring the GTP-bound state that accelerates cell proliferation and migration when expressed in normal melanocytes. Screens uncovered other mutations at recurrent positions in PPP6C that reduce the phosphatase's catalytic activity, consequently dysregulating the kinase AURKA and causing chromosome instability 4, 5 . Frequent inactivating mutations were also discovered in the tumor suppressors TP53, NF1 and ARID2, and less frequent mutations were found in TACC1, GRM3, MAP3K4 and MAP3K9 that are likely to enhance melanoma pathogenesis 6, 7 . Furthermore, recent studies have shed light on variants in regulatory regions of the melanoma genome. Recurrent mutations in the TERT promoter, which alter a transcription factor-binding motif and possibly lead to increased expression of TERT, shield melanoma cells from senescence 8, 9 .
Recent years have seen unprecedented growth in the understanding of genetic and genomic changes in melanoma. Much of the information is from next-generation sequencing (NGS), particularly exome sequencing, and has been instrumental in the discovery of new cancerdriver genes. These NGS studies have corroborated the previously identified frequent recurrent somatic mutations in BRAF and NRAS and revealed new melanoma mutations, including a recurrent mutation in RAC1 (RAC1 P29S ), the third most frequent activating mutation in sun-exposed melanoma after BRAF and NRAS, and the most frequent recurring mutation in the Rho GTPase family [1] [2] [3] . The mutant protein RAC1 P29S is a fast-cycling GTPase favoring the GTP-bound state that accelerates cell proliferation and migration when expressed in normal melanocytes. Screens uncovered other mutations at recurrent positions in PPP6C that reduce the phosphatase's catalytic activity, consequently dysregulating the kinase AURKA and causing chromosome instability 4, 5 . Frequent inactivating mutations were also discovered in the tumor suppressors TP53, NF1 and ARID2, and less frequent mutations were found in TACC1, GRM3, MAP3K4 and MAP3K9 that are likely to enhance melanoma pathogenesis 6, 7 . Furthermore, recent studies have shed light on variants in regulatory regions of the melanoma genome. Recurrent mutations in the TERT promoter, which alter a transcription factor-binding motif and possibly lead to increased expression of TERT, shield melanoma cells from senescence 8, 9 .
NGS has also fostered an increased understanding of the genetics of noncutaneous melanomas, with the discovery of frequent mutations in BAP1, EIF1AX and SF3B1 in uveal melanoma 10, 11 .
We report here the results of WES analysis of 213 human melanoma samples, including samples from 109 patients that we studied previously 3 (Supplementary Data). Matched normal DNA was sequenced and analyzed from 133 of the tumors. We also tested the response of melanoma cell lines to the MEK inhibitor selumetinib (AZD6244), currently in clinical trials, and to the ERK inhibitor SCH772984 and performed protein blot analyses to correlate the effects of specific mutations with drug response. splice-site variant or insertion-deletion (indel) mutations 12 . The top 40 ranked genes from this analysis are shown in Table 1 (details are also provided in the Supplementary Data). Among those, we identified 11 genes that exhibited statistically significant mutation counts above what was expected on the basis of a driver gene analysis by MutSigCV 13 ( Fig. 1 and Supplementary Data) .
Three genes were mutated with an incidence greater than 10%: BRAF and NRAS, with known recurrent activating mutations, and NF1, with a high number of inactivating mutations. In our cohort, we observed BRAF V600 mutations in 38.5% of melanomas (82 of 213) and RAS Q61/G12/G13 mutations (58 NRAS and 3 HRAS) in 28.6% (61 of 213), and two melanomas were BRAF-NRAS double mutants ( Table 2) . Ninety percent of the NF1-mutant melanomas (38 of 42) harbored mutations of the inactivating or predicted damaging type ( Supplementary Fig. 1 and Supplementary Data), with the majority (26 of 38) in melanomas expressing wild-type BRAF-RAS, as noted previously by our group 3 and recently by The Cancer Genome Atlas (TCGA) consortium 14 ; two NRAS Q61R -mutant, one KRAS G12I -mutant and nine BRAF V600 -mutant melanomas had concurrent NF1 mutations. Among the tumors with no detectable BRAF or RAS mutation, a total of 46.4% (26 of 56) were NF1 mutants ( Table 2) . Of those, more than 80% (21 of 26) either showed loss of heterozygosity (LOH) across the NF1 locus or were compound heterozygotes harboring two NF1 mutations. Conversely, of the 12 BRAF-mutant or RAS-NF1 doublemutant melanomas, one-third (4 of 12) showed LOH or compound heterozygosity (Supplementary Data).
NF1-mutant melanomas harbored significantly more somatic mutations (P = 1.5 × 10 −10 ) and occurred in significantly older patients (P = 0.017), but they were associated with similar overall patient survival compared to BRAF-mutant, RAS-mutant and 'triple-wild-type' (BRAF-RAS-NF1-wild-type) melanomas ( Fig. 1 and Supplementary Fig. 2 ).
Mutations in known melanoma-driver genes affecting cell proliferation and survival, including RAC1, PTEN, CDKN2A, MAP2K1 and RB1, were also detected. This list included the X-chromosome gene FAM58A, which harbored several inactivating mutations. FAM58A (also known as cyclin M) negatively regulates RAF1 expression via interaction with CDK10, and mutations in FAM58A cause the inherited human developmental disease STAR syndrome 15 . Early-termination alterations in FAM58A were present in four tumors from male patients. All of the tumors were BRAF-RAS wild type; two were NF1-mutant and the other two were triple-wild type. The analysis also showed a recurrent R18W mutation in BCL2L12, which encodes an anti-apoptotic factor 16 . This mutation was adjacent to F17F, a recurrent silent mutation with increased inhibitory potential against UV-induced apoptosis due to increased BCL2L12 gene transcript and protein levels 17 .
Mutations in genes involved in chromatin modification or DNA repair were identified, some for the first time in melanoma. The list included two SWI/SNF family members, ARID1A (linked to gastric cancers 18 ) and ARID2, reiterating the role of chromatin remodeling in malignancy. An additional gene in this category was the polycomb protein-encoding gene EZH2, which is upregulated in melanoma 19 ; we noted recurrent EZH2 Y646N mutations in four tumors. The mutation was located in the SET domain, which is involved in histone methylation 20 . A considerable number of inactivating mutations were in histone modifiers. Mutations were identified in KMT2B (MLL2) and SETD2, the latter of Figure 1 Melanoma mutational landscape (n = 213). Top 11 melanoma-driver genes that reach genome-wide significance according to background mutation-frequency estimation. Purple, metastatic melanoma; green, patients over 65 years old; red, mutations at recurrent positions; dark blue, inactivating mutations (nonsense, splice, indel); light blue, predicted harmful mutations. Brown and darker orange represent sun-exposed tumors and tumors of unknown origin, respectively. Mutations in HRAS and KRAS are marked in light orange and yellow, respectively. Mutation counts correspond to novel mutations that are not found in repositories of common human variants.
A r t i c l e s which is a recognized tumor suppressor in renal cell carcinoma 21 , as well as in TRRAP, involved in histone acetylation, which showed a previously described recurrent TRRAP S722F mutation 22 .
Finally, in the metabolism category, we found 22 mutations in CYP7B1, some of which occurred at recurrent positions (H286Y, E321K and P338S), suggesting an important role for cytochrome P450 in melanoma. Diminished expression of CYP7B1 is associated with breast cancer, possibly through modification of cholesterol metabolism 23 . We also observed a recurrent IDH1 R132C mutation in four tumors. IDH1 R132C , frequently present in glioma 24 is a neomorphic mutation that causes production of D-2-hydroxyglutarate rather than the normal product, α-keto glutarate 25 .
NF1-mutant melanomas harbor co-mutations in RASopathy genes
A search for subtype-specific variants showed that damaging mutations in RASA2, which encodes a GTPase-activating protein that suppresses RAS function 26 , were exclusively present in NF1-mutant melanomas that were BRAF-RAS wild type (P = 0.006; Supplementary Data). Of the nine RASA2 mutations, two were nonsense and three were recurrent at position R551C. Four of the seven RASA2-mutant tumors showed LOH across the locus (all with a single RASA2 mutation), and two were compound heterozygotes. The recurrent RASA2 R511C variant was recently described in the germline of a patient with Noonan syndrome 27 , a RASopathy otherwise linked to mutations in SOS1, PTPN11, RAF1 and other genes affecting RAS-MAPK signaling 28 . A search across these genes showed that four NF1-mutant, BRAF-RAS-wild-type melanomas harbored disease-causing mutations in PTPN11, with p.Tyr279Cys, p.Ala461Thr, p.Pro491Leu and p.Glu506Pro linked to the Noonan and LEOPARD syndromes 29, 30 . Two NF1-mutant, BRAF-RAS-wild-type melanomas harbored mutations in SOS1 linked to Noonan syndrome (p.Gly434Arg and p.Arg552Lys) [31] [32] [33] , and another two had mutations in RAF1 (p.Pro261Leu and p.Thr491Ile) that were also associated with Noonan syndrome 34 . NF1-mutant melanomas also featured mutations in SPRY and Sprouty-related genes known to encode negative regulators of MAPK signaling. In particular, three NF1-mutant melanomas harbored protein-coding alterations in SPRED1, including earlytermination mutations. SPRED1 enhances NF1 activity by recruiting the protein to the plasma membrane 35 , and early-termination mutations in SPRED1 are linked to Legius syndrome (another RASopathy), which is characterized by neurofibromatosislike skin features such as multiple café-au-lait macules, but not neurofibromas 36 .
In all, out of 26 NF1-mutant, BRAF-RAS-wild-type melanomas, ~60% (15) carried mutations in known RASopathy genes RASA2, PTPN11, SOS1, RAF1 and SPRED1, the majority of which (10 of 15) were documented disease-causing mutations ( Table 3 and Supplementary Data).
Although the occurrence of RASopathy gene mutations was significantly associated with NF1-mutant, BRAF-RAS-wild-type melanomas (P = 0.0004; Supplementary Data), 8 .6% (16 of 187) of the remaining melanomas in our cohort also featured mutations in these genes ( Supplementary Fig. 3 ). Mutations in three of these genes were thought to be disease causing: (1) two early-termination mutations in SPRED1 (in two different tumors, one with BRAF V600E and another with NRAS Q61L mutation); (2) p.Asn58Ser in PTPN11, a known gain-of-function mutation in lung cancer 37 that occurred in a melanoma with NRAS Q61R ; and (3) a p.Met269Lys SOS1 mutation in a triple-wild-type melanoma. The mutated residue in SOS1 (p.Met269) has documented associations with Noonan syndrome 38 .
Of interest, the pathogenic PTPN11 P491L and MAPK1 D321V , the latter a mutation in the docking site for DUSP-ERK interaction, were present in YUKLAB NF1 H729Q/R1204W/R416* melanoma. The protein encoded by MAPK1 D321V is similar to the known D321N, which impairs binding to DUSPs and reduces the sensitivity to inactivation by phosphatases 39 . Finally, two NF1-mutant melanomas (YUROG NF1 Q1218* and YUCAS NF1 FS-Indel ) contained KRAS A146T and KRAS Q22K , respectively, known activating mutations in colorectal cancer 40 .
NF1 mutations, NF1 expression and RAS activation NF1 negatively regulates RAS by enhancing its RAS GTPase activity, converting active RAS-GTP to inactive RAS-GDP. We therefore investigated NF1 expression and NRAS activity in our exomesequenced melanoma cell lines. Protein blot analysis showed that 75% of NF1-mutant melanomas (six out of ten), all BRAF-NRAS wild type, did not express NF1 or expressed it at low levels ( Fig. 2a and Supplementary Fig. 4 ). One melanoma, YUDAB, homozygous for NF1 F1464L mutation, did not express the protein, perhaps because of protein instability. Interestingly, the two NF1-mutant melanomas that expressed NF1 were also BRAF V600E mutants. One of them was from a neurofibromatosis patient with a germline NF1 frameshift mutation. This sample showed levels of NF1 expression about half those found in normal human melanocytes (YUSAMIR; Fig. 2a ). Figure 2 also shows that two NF1-wild-type melanomas (YUHOIN and YUDATE) did not express NF1, and both showed LOH across the NF1 locus. RAF pulldown assay showed that loss or low levels of NF1 were associated with the presence of activated GTP-bound RAS in most but not all cases (Fig. 2b,c) , demonstrating the likely involvement of other RAS regulators.
NF1 expression and drug response
One of the main goals of identifying driver mutations in cancer is to make it easier to choose an appropriate targeted therapy, such as vemurafenib or dabrafenib, drugs that inhibit mutant BRAF melanomas, for the treatment of patients with BRAF V600 -mutant tumors 41, 42 . Loss of NF1 expression was suggested to mediate resistance to the MEK inhibitor selumetinib (AZD6244) in one report 43 and to be a biomarker for high sensitivity to the MEK inhibitor PD0325901 in another 44 . A more recent study showed that NF1-negative and NF1-positive melanoma cell lines display the same sensitivity to the MEK inhibitor trametinib 45 . We therefore tested the effect of selumetinib, which is currently in clinical trials, on a panel of 21 melanoma cell lines, 10 NF1 mutants (or null by LOH) and 11 NF1 wild type, all characterized by exome sequencing (Fig. 3) . The data showed that 60% of the NF1-mutant melanoma cell lines (six out of ten) were highly sensitive (IC 50 of 0.036 µM or below), and four were highly resistant (IC 50 of 2.1-10 µM) (Fig. 3a) , indicating that suppression of NF1 is not always associated with sensitivity or resistance to a MEK inhibitor as was previously suggested 43, 44 . Seven of the ten NF1-mutant, BRAF-NRAS-wild-type melanoma cell lines did not express NF1 or expressed it at extremely low levels (Fig. 2a) . Of those, ~43% (three out of seven) were sensitive to MEK inhibition. 
A r t i c l e s
All three double-mutant melanoma cell lines in this panel were sensitive to selumetinib. These included YURKEN, which carries NF1 P228S -BRAF V600E mutation (IC 50 = 0.028); YUTICA, which harbors NF1 P166L -NRAS Q61R mutation; and YUSAMIR, an NF1 FS indel-BRAF V600E mutant from a person with neurofibromatosis (Fig. 3a) . All three expressed high levels of NF1 (Fig. 2a) . Also, YURKEN was highly resistant to the BRAF inhibitor vemurafenib, whereas YUSAMIR was highly sensitive to the drug ( Supplementary  Fig. 5 ). The results suggest that patients with double mutations should not be a priori excluded from vemurafenib treatment on the basis of expected resistance to the drug 43, 44 .
Melanoma cell lines that did not carry an NF1 mutation showed diverse sensitivity to selumetinib, with an IC 50 range of 0.003-0.374 µM, and ~55% (6 of 11) showed only a cytostatic response (Fig. 3b) .
We also tested the response to SCH772984, a selective ATPcompetitive ERK inhibitor that is in phase I clinical trials. Again, the highly selumetinib-resistant NF1-null YUHOIN and YUHEF melanoma cells were also the most resistant to this ERK inhibitor (Fig. 3c) . However, in general, drug response followed a similar distribution in the NF1-null, triple-wild-type and BRAF-NRAS mutant melanoma cell lines (Fig. 3c,d) .
We explored the possibility that selumetinib induces upstreampathway activation that is more prominent in NF1-null resistant cells than in sensitive cell lines, as this was suggested to characterize MEK resistance 44 . Protein blot analyses showed increased levels of phosphorylated MEK (pMEK) in all melanoma cells that did not carry the BRAF V600E/K mutation (i.e., NF1-null, NRAS Q61R/L -mutant and even normal human melanocytes), regardless of the cells' sensitivity to selumetinib in cell proliferation assays (Fig. 4a,b) . Furthermore, although pERK was suppressed within an hour in response to selumetinib in all cell lines, its rebound at later time points was not indicative of resistance to the drug. For example, pERK did not recover in the resistant YUHEF cell line at the end of 24 h of treatment with 100 nM selumetinib, whereas it did recover in the resistant YUSOC and YUHOIN lines, as well as in the sensitive cell line YUDAB (Fig. 4a) . Taken together, the data show that the feedback that leads to ERK activation in response to selumetinib in NF1-null melanoma cells is not necessarily associated with resistance to the drug, and that pERK phosphorylation is not required for selumetinib resistance.
Somatic copy-number alterations in triple-wild-type melanomas
We derived the genomic copy-number status and somatic copynumber alterations (SCNAs) on the basis of differences in read coverage between normal and matched tumor samples. Recent bioinformatics approaches allow for the long-range prediction of SCNAs by means of exome sequencing 46 . The corresponding SCNA segments can then be analyzed for broad and focal amplified and deleted regions with downstream programs such as GISTIC 47 . The GISTIC results for our matched melanoma samples are listed in the Supplementary Data and are presented graphically in Supplementary  Figure 6 . We observed known deletions in 9p21.3 (CDKN2A), 17p13.1 (TP53) and 10q23.31 (PTEN) and amplifications in 1q31.3 (ASPM) and 7q34 (BRAF). We identified a significant amplification signal in 7p22.1, near the PMS2 locus, and an amplification peak in 5p15.33, which harbors TERT. The latter supports the role of telomerase maintenance in melanoma based on recurrent somatic mutations in the TERT promoter 8, 9 .
We also conducted GISTIC analysis with a focus on triple-wild-type melanomas, specifically, 19 matched melanomas that were wild type for BRAF, RAS and NF1. The analysis revealed a distinctive amplification peak at 4q12, harboring the KIT-KDR locus ( Supplementary  Fig. 7 ) that was present in two melanomas. KIT and KDR are receptor tyrosine kinases that activate the MAPK pathway 48, 49 . Triplewild-type melanomas carried additional characteristic copy-number alterations, including an amplification peak in MAP3K8 in YUROL that was not seen in any other melanoma specimen ( Supplementary  Fig. 8a,b) . MAP3K8 expression has been implicated as a resistance mechanism to BRAF-inhibitor therapy in melanoma 50 . Another amplification peak was seen in YUDATE melanoma that included the MAPK1 (ERK2) locus (Supplementary Fig. 8c ).
DISCUSSION
The genome-wide mutational analysis of melanoma reinforces the role of known frequent mutations in this devastating cancer and enhances our understanding of the processes that lead to melanomagenesis. This study showed that sun-exposed melanomas harbored a large number of missense mutations, but only a few were of the gain-offunction type characteristic of oncogenes such as BRAF, NRAS, RAC1, MAP2K1, EZH2 and IDH1 that are amenable to targeted therapy. In fact, mutations at recurrent positions can be of the inactivating type, as was demonstrated for PPP6C 5 . The majority of the loss-of-function changes affect processes involved in cell cycle progression; chromatin remodeling, DNA repair and/or transcription including histone methyltransferases (KMT2A, SETD2); and members of the SWI/SNF (Fig. 3) . The types of NF1 and RAC1 mutations are indicated for each cell line at the top. All the cell lines in b express wild-type RAC1. Figure 2a and supplementary Figure 4 show the corresponding levels of NF1 expression. The results represent one of two similar experiments. npg complex (ARID2 and ARID1A). Together these changes are likely to modify gene expression that releases normal cellular safeguards or constraints for which the design of inhibitors is more challenging.
The results of our large-scale exome sequencing highlight NF1 as a major player in melanomagenesis. In our cohort, 46% of BRAF-RAS-wild-type melanomas harbored NF1 mutations, which are often associated with LOH due to hemizygous deletions or copy-neutral gene conversions, or carried two or more single-nucleotide variants, suggesting biallelic mutation. NF1-BRAF and NF1-RAS doublemutants displayed considerably less LOH and fewer biallelic NF1 mutations (4 out of 12) than did NF1-mutant, BRAF-RAS-wild-type melanomas (21 of 26), and when tested they were found to express normal or high levels of NF1, suggesting a minor role for this tumor suppressor in these melanomas. In contrast, all of the NF1-mutant, BRAF-NRAS-wild-type melanomas did not express NF1. The loss of NF1 expression led to increased RAS activation in most but not all of these cases; RAS relative activity remained low in two out of the six NF1-null melanoma cell lines, probably because of the effects of other RAS-GTPase-activating proteins.
We found that NF1-null melanoma cell lines could be either sensitive or resistant to MEK or ERK inhibitors. We searched for additional mutations that may confer resistance to these inhibitors by activating alternative signaling pathways. Two of the three selumetinib-resistant NF1-mutant melanomas also carried the RAC1 P29S mutation (YUHEF and YUSOC), in line with a recent publication indicating that RAC1-mutant melanomas are relatively resistant to MEK inhibitors 51 . However, the YUTOGS melanoma is also a RAC1 P29S -NF1 doublemutant but was highly sensitive to selumetinib (IC 50 = 0.022 µM). We speculate that other damaging mutations could facilitate activation of the phosphoinositide 3-kinase (PI3K)-mTOR pathway. For example, YUHEF melanoma carries three mutations in the RASopathy gene SOS1 (p.Pro102Ser, p.Arg398Gly and p.Gly434Val) that may confer constitutive RAS activity, and PHLPP2 mutations are present in YUSOC (p.Pro142Ser) and YUHEF (p.Ser915Phe). PHLPP1 and PHLPP2 (similar to PTEN, which was not altered in these cells) are phosphatases that target AKT, PKC, S6K and RAF1, and their inactivation has been demonstrated in other cancers 52 . Furthermore, downregulation of PHLPP1 increases AKT activity, enhances the proliferation of melanoma cells and melanocytes and results in anchorage-independent growth of melanocytes 53 .
Neurofibromatosis is a genetic disorder that affects the nervous system and causes benign cutaneous neurofibromas and elevated risk for multiple Schwann cell tumors 54 . Epidemiological studies show that there is a general increase in the incidence of 13 other cancers among people with neurofibromatosis, albeit at a much lower rate, and melanoma is one of them 55 . Interestingly, melanocytes from café-au-lait macules of NF1 patients carry a somatic or second-hit mutation in NF1, indicating that a loss of NF1 provides a growth stimulus to normal melanocytes but does not accelerate their malignant transformation 56 . One possibility is that NF1 loss may be a more effective NRAS activator in the nervous system than in melanocytes 57 . Another likely explanation may relate to the timing of the mutation, with inherited loss of NF1 leading to the neurofibromatosis phenotype, and somatic mutations later in life, accompanied by additional alterations, leading to a variety of human cancers 58 . A similar observation has been made for retinoblastoma: although small-cell lung cancers show some of the highest somatic RB1 mutation rates, longterm retinoblastoma survivors with RB1 germline mutations have only a slightly increased incidence of secondary lung cancers 59 .
We identified documented disease-causing mutations in RASopathy genes RASA2, PTPN11, SOS1, RAF1 and SPRED predominantly in NF1-mutant melanomas, but also in BRAF-RAS mutant and triplewild-type tumors, to a lesser degree. To our knowledge this is the first report to describe the presence of several known RASopathy gene mutations in melanoma, highlighting a possible role for these altered genes in cancer pathogenesis. Most of these mutations are found in NF1-mutant melanomas, and our functional studies showed that a loss of NF1 expression did not always lead to NRAS activation. These results raise the intriguing possibility that NF1-mutant melanomas may require additional changes for robust MAPK pathway activation. Indeed, clinically, concurrent NF1 and PTPN11 mutations cause severe or lethal forms of Noonan syndrome 60, 61 . There is a case of a child with concurrent NF1 and PTPN11 mutation who developed bilateral optic nerve glioma, whereas the remaining family members, who carried only an NF1 mutation, displayed mild neurofibromatosis symptoms (café-au-lait spots) 62 . In addition, there is evidence that a loss of NF1 expression enhances the activity of noncanonical RAS mutations 63 , which is relevant to our observation of two cases of NF1-mutant melanomas, one with KRAS A146T mutation and the other with KRAS Q22K mutation.
METhODS
Methods and any associated references are available in the online version of the paper.
Accession codes. The entire data set has been deposited in dbGAP under accession number phs000933. be sufficient for calling heterozygous mutations with our mutation-calling thresholds and level of coverage. Review of selected samples and/or slides by a pathologist showed agreement with the automated analysis, with a mean purity of 71.7% across 24 paired and unpaired samples (Supplementary Data).
Sequencing statistics. For our tumor samples, we calculated a mean error rate of 0.2% ± 0.08% per called SNV, a mean coverage of 204 ± 76 independent reads per base, and coverage of at least eight independent reads across 96.5% ± 3% of the covered bases. Our matched normal samples were sequenced with a slightly smaller coverage of 141 ± 42 independent reads per base.
Variant-call precision. We Sanger validated 418 novel SNVs that were called using our variant-calling pipeline. We measured a precision of 93%, corresponding to 389 true positive and 29 false positive variant calls.
Protein blot analyses. Cell pellets were lysed in RIPA buffer supplemented with protease and phosphatase inhibitors, and the levels of proteins were estimated with the Bio-Rad kit (Bio-Rad Laboratories). For NF1 analysis, cell extracts from different melanomas (20 µg/lane) were subjected to protein blot analysis with a 3%-8% Tris-acetate gel, Tris-acetate SDS running buffer and NuPAGE transfer buffer (Life Technologies, NP0006). The membranes were probed with anti-NF1 (Bethyl Laboratories, A300-140A) followed by anti-β-actin monoclonal antibody (clone AC-74, A5316, Sigma-Aldrich) as a control for protein loading. For MEK signaling pathway analysis, normal human melanocytes and melanoma cells were either untreated or treated with 100 nM selumetinib (Selleckchem Chemicals, S1008). Cells were harvested 1, 6, and 24 h later, and cell lysates were subjected to protein blot analysis in 4-12% Bis-Tris gels (Novex) as described 64 . The antibodies used were to phospho-MEK1/2 pSer217/221 (9121), MEK1/2 (4694), phospho-ERK2 pThr202/Tyr204 (9106), and ERK1/2 (4695), all from Cell Signaling Technology.
